Activity Overview
Neuromuscular junction disorders encompass a broad range of conditions with overlapping symptomatology, including generalized myasthenia gravis, Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, and several others. Overreliance on any single serological or electrophysiological test can lead to misdiagnosis and prolonged diagnostic and treatment delays. This CE-certified program provides neuromuscular specialists, general neurologists, and other clinicians who evaluate these patients with a practical framework for recognizing distinguishing clinical features, building a differential diagnosis, and applying diagnostic criteria to reach timely and accurate diagnoses.
Target Audience
This activity is intended for neuromuscular specialists, neurologists, nurse practitioners, physician assistants, and nurses who treat neuromuscular diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review differing clinical features of neuromuscular disorders
- Develop a differential diagnosis for patients with suspected neuromuscular disorders
- Implement diagnostic criteria to identify patients with neuromuscular disorders in a timely manner
Ali A. Habib, MD
Clinical Professor of Neurology
Director, Neuromuscular Medicine Fellowship
Neuromuscular Division
Department of Neurology
University of California
Irvine, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Alexion Pharmaceuticals/AstraZeneca, Amgen, Arcellx, argenx, Bristol Myers Squibb, Cabaletta Bio, Cartesian, Cour Pharmaceuticals, Grifols, Immunovant, Janssen/Johnson & Johnson, Merck, Nkarta, NMD Pharma, Novartis, Regeneron, UCB; Speakers Bureau: Alexion Pharmaceuticals, argenx, Janssen/Johnson & Johnson, UCB; Grant/Research Funding: Alexion Pharmaceuticals/AstraZeneca, Amgen, Arcellx, argenx, Bristol Myers Squibb, Cabaletta Bio, Cartesian, Cour Pharmaceuticals, Grifols, Immunovant, Janssen/Johnson & Johnson, Merck, Nkarta, NMD Pharma, Novartis, Regeneron, UCB; Ownership Interests in Publicly Traded Companies: Cartesian, Kyverna Therapeutics.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here